Group 1 - The stock of Baixin An-B (02185) experienced a significant increase, rising over 15% during trading, reaching a high of 10.77 HKD, marking a new high in over two years, with a closing increase of over 50% the previous day [1] - As of the report, the stock price is up 7.63%, currently at 10.01 HKD, with a trading volume of 61.17 million HKD [1] Group 2 - The American Heart Association (AHA) and the American College of Cardiology (ACC) have released an updated guideline for the prevention, detection, assessment, and management of adult hypertension, which includes significant revisions from the 2017 version [1] - The new guidelines aim to provide more precise clinical practice guidance to reduce cardiovascular disease (CVD) risk, with renal denervation (RDN) being introduced as a newly recommended treatment option [1] - Additionally, there are reports that the Centers for Medicare & Medicaid Services (CMS) in the U.S. has proposed a new RDN insurance coverage plan for patients with uncontrolled hypertension, which is currently in a 30-day public comment period, with a final decision expected by October 8, 2025 [1]

Core Viewpoint - The stock of Baixinan-B (02185) experienced significant volatility, with a peak increase of over 15% and a closing rise of more than 50% recently, indicating strong market interest and potential investor confidence in the company [1]. Group 1: Market Reaction - Baixinan-B's stock price rose by 11.4% to HKD 10.36, with a trading volume of HKD 42.644 million [1]. Group 2: Industry Developments - The American Heart Association (AHA) and the American College of Cardiology (ACC) released updated guidelines for the prevention, detection, assessment, and management of adult hypertension, marking significant revisions from the 2017 guidelines [1]. - The new guidelines include updates on the diagnosis, risk assessment, and treatment of hypertension, aiming to provide more precise clinical guidance to reduce cardiovascular disease (CVD) risk [1]. - Renal denervation (RDN) has been added as a recommended treatment option in the updated guidelines [1]. Group 3: Regulatory Changes - The Centers for Medicare & Medicaid Services (CMS) proposed a new RDN insurance coverage plan for patients with uncontrolled hypertension, which is currently in a 30-day public comment period [1]. - The final decision on the new RDN insurance proposal is expected to be announced by October 8, 2025, or earlier [1].

Core Viewpoint - The stock of Baixinan-B (02185) experienced significant volatility, with a rise of over 50% recently, driven by updates in hypertension management guidelines and potential insurance coverage for renal denervation (RDN) procedures [1]. Group 1: Stock Performance - Baixinan-B's stock rose over 15% at one point and closed up more than 50% yesterday, currently trading at 10.36 HKD with a trading volume of 42.644 million HKD [1]. Group 2: Industry Guidelines - The American Heart Association (AHA) and the American College of Cardiology (ACC) released updated guidelines for the prevention, detection, assessment, and management of adult hypertension, marking significant revisions from the 2017 guidelines [1]. - The new guidelines include updates on the diagnosis, risk assessment, and treatment of hypertension, aiming to provide more precise clinical guidance to reduce cardiovascular disease (CVD) risk [1]. Group 3: Insurance Coverage Proposal - The Centers for Medicare & Medicaid Services (CMS) proposed new insurance coverage for RDN, suggesting it be included for patients with uncontrolled hypertension [1]. - The proposal has entered a 30-day public comment period, with a final decision expected to be announced by October 8, 2025 [1].